Report from the extra general meeting
At the extra general meeting (EGM) of ChronTech Pharma AB (below ”the Company”) on the 6th of May, 2013 it was resolved to reduce the share capital by means of redemption and cancellation of shares and to amend the articles of association. The resolution means that the share capital will be reduced by SEK 2,408,228.85 to cover losses by means of redemption and cancellation of 80,274,295 shares. The shares that will be redeemed and cancelled are owned by the group of shareholders that will buy approximately 70 per cent of the Company’s project regarding development of DNA vaccines against hepatitis B and hepatitis C. In order to enable the reduction of the share capital, it was resolved to amend the provisions of the articles of association regarding the limits of the share capital and the number of shares. The share capital shall amount to not less than SEK 3,000,000 and not more than SEK 12,000,000. The number of shares shall amount to not less than 100,000,000 and not more than 400,000,000.
For more information, please contact:
Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB
Mobile phone: +46 709 28 05 28
ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se
In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.